TABLE 3.
Discriminative performance of aneurysm wall enhancement
| Study | Design | Outcome | AWE groups | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) | Reproducibility | |
|---|---|---|---|---|---|---|---|---|---|
| Inter‐rater | Intra‐rater | ||||||||
| Edjlali et al. [35] | CS | Rupture | No/focal thick/ circumferential thin/circumferential thick (>1 mm) | 88 (70–98) | 62 (56–67) | 18 (12–26) | 98 (95–100) | NR | NR |
| Omodaka et al. [27] | CS | Rupture | Quantitative: CRstalk (cutoff value 0.64) | 75 (55–89) | 83 (73–91) | 62 (44–78) | 90 (80–96) | ICC: 0.98 (0.95–0.99) | ICC: 0.98 (0.94–0.99) |
| Wang et al. [26] | CS | Rupture | No/partial/entire | 100 (82–100) | 26 (18–37) | 23 (14–33) | 100 (85–100) | NR | NR |
| Nagahata et al. [29] | CS | Rupture | No/faint/stronga | 98 (91–100) | 82 (72–90) | 80 (69–88) | 99 (92–100) | NR | NR |
| Matsushige et al. [28] | CS | Growth | Present/absent | 46 (27–67) | 85 (68–67) | 71 (44–90) | 67 (50–80) | 0.93 (0.80–1.00) | NR |
| Edjlali et al. [35] | CS | Growth + symptomatic | No/focal thick/ circumferential thin/circumferential thick (>1 mm) | 71 (52–86) | 62 (56–67) | 17 (11–25) | 95 (91–98) | 0.82 (0.67–0.99) | 0.87 (0.74–1.0) |
| Fu et al. [34] | CS | Symptomatic | No/focal/circumferential | 82 (72–89) | 69 (63–75) | 50 (41–58) | 91 (86–95) | NR | NR |
| Wang et al. [31] | CS | Symptomatic | No/partial/entire | 100 (89–100) | 43 (30–57) | 48 (36–61) | 100 (86–100) | NR | NR |
| Zhu et al. [32] | CS | Symptomatic | Grade 0/1/2b | 94 (86–98) | 67 (56–76) | 72 (62–80) | 92 (82–97) | NR | NR |
| Zhong et al. [33] | CS | Symptomatic | No/partial/circumferential | 76 (58–89) | 69 (57–79) | 50 (36–64) | 87 (77–94) | NR | NR |
| Omodaka et al. [30] | CS | Growth + symptomatic | Quantitative: CRstalk (cutoff value 0.39) | 88 (70–98) | 62 (50–74) | 47 (33–62) | 93 (82–99) | NR | NR |
| Vergouwen et al. [25] | L | Growth + rupture | Present/absent | 100 (40–100) | 75 (63–86) | 21 (6–46) | 100 (92–100) | NR | NR |
| Gariel et al. [24] | L | Growth | Present/absent | 83 (52–98) | 59 (50–67) | 15 (8–26) | 97 (91–100) | NR | NR |
The data from the different AWE groups were used in such a way that the discriminative performance parameters reflect the performance of “any enhancement”.
Reproducibility values are kappa values unless stated otherwise, and only reported if relating to “any enhancement”. Studies are arranged based on study design and outcome.
Data in parentheses are 95% confidence intervals.
Abbreviations: AWE, aneurysm wall enhancement; CS, cross‐sectional; ICC, intraclass correlation coefficient; L, longitudinal; NR, not reported.
a’Strong’ is definite enhancement equal to choroid plexus or venous plexus and ‘faint’ is increased wall signal intensity compared to precontrast scan.
bGrade 0 is no enhancement, grade 1 is enhancement more than normal vessel wall, grade 2 is enhancement greater than pituitary infundibulum.